Following the successful approval and commercialization of PARP inhibitors, there has been an increasing number of DNA damage response drugs moving into and advancing through the clinic. This industry focused summit will enable you to stay ahead of the game and understand how leading pharma and biotech decision makers are:
Pick the brains of 80+ senior industry peers from the likes of AstraZeneca, Tesaro, Pfizer, Repare Therapeutics, Ideaya, Abbvie, Celgene and many more, to help you tackle your challenges and improve your research strategy.
What to expect:
“This is a very informative meeting with the right experts and relevant topics.”
“Well organized and focused meeting covering all aspects of current challenges and achievements on synthetic lethal interactions.”